Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Abed Y, Fage C, Lagüe P, Carbonneau J, Papenburg J, Vinh DC, Boivin G.

Emerg Infect Dis. 2019 Apr;25(4):838-840. doi: 10.3201/eid2504.181554.

2.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

3.

Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.

MBio. 2013 Jul 16;4(4). pii: e00396-13. doi: 10.1128/mBio.00396-13.

4.

Systematic review of influenza resistance to the neuraminidase inhibitors.

Thorlund K, Awad T, Boivin G, Thabane L.

BMC Infect Dis. 2011 May 19;11:134. doi: 10.1186/1471-2334-11-134. Review.

5.

Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.

Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y.

Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

PMID:
23267831
6.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
7.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
8.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

9.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

10.

Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 May;54(5):1834-41. doi: 10.1128/AAC.01608-09. Epub 2010 Mar 1.

11.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

12.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.

13.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
14.

Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

Baz M, Abed Y, McDonald J, Boivin G.

Clin Infect Dis. 2006 Dec 15;43(12):1555-61. Epub 2006 Nov 8.

PMID:
17109288
15.

I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.

LeGoff J, Rousset D, Abou-Jaoudé G, Scemla A, Ribaud P, Mercier-Delarue S, Caro V, Enouf V, Simon F, Molina JM, van der Werf S.

PLoS One. 2012;7(8):e37095. doi: 10.1371/journal.pone.0037095. Epub 2012 Aug 24.

16.

Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.

Fujisaki S, Imai M, Takashita E, Taniwaki T, Xu H, Kishida N, Yokoyama M, Sato H, Tashiro M, Odagiri T.

J Infect Chemother. 2013 Oct;19(5):891-5. doi: 10.1007/s10156-013-0589-6. Epub 2013 Mar 26.

PMID:
23529501
17.

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Hurt AC, Holien JK, Parker M, Kelso A, Barr IG.

J Virol. 2009 Oct;83(20):10366-73. doi: 10.1128/JVI.01200-09. Epub 2009 Jul 29.

18.

E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.

L'Huillier AG, Abed Y, Petty TJ, Cordey S, Thomas Y, Bouhy X, Schibler M, Simon A, Chalandon Y, van Delden C, Zdobnov E, Boquete-Suter P, Boivin G, Kaiser L.

J Infect Dis. 2015 Dec 1;212(11):1726-34. doi: 10.1093/infdis/jiv288. Epub 2015 May 17.

19.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

20.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.

Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.

Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.

Supplemental Content

Support Center